PO-156 URINARY MORBIDITY RELATED TO PROSTATE BRACHYTHERAPY WITH OR WITHOUT EXTERNAL BEAM RADIATION THERAPY
β Scribed by M. Ishida; K. Kanao; A. Sugawara; R. Ohara; S. Kashiyama; M. Katayama; N. Tsukamoto; Y. Nakajima
- Book ID
- 117361741
- Publisher
- Elsevier Science
- Year
- 2012
- Tongue
- English
- Weight
- 79 KB
- Volume
- 103
- Category
- Article
- ISSN
- 0167-8140
No coin nor oath required. For personal study only.
π SIMILAR VOLUMES
## Abstract ## BACKGROUND Prostate brachytherapy is increasingly used to treat prostate carcinoma, alone or combined (combination therapy) with external beam radiation therapy (EBRT). This report cites the frequency and nature of urinary and rectal complications requiring unplanned interventions a
The purpose of this analysis was to correlate isotope selection with the urinary symptoms of patients who received a combination of external beam radiotherapy (EBRT) and a transperineal interstitial permanent prostate brachytherapy (TIPPB) boost with either a 103 palladium ( 103 Pd) or a 125 iodine
## Abstract ## BACKGROUND This study was designed to estimate the rates of late genitourinary (GU) and rectal toxicity after magnetic resonance image (MRI)βguided prostate brachytherapy exclusively or in conjunction with external beam radiation therapy (EBRT). ## METHODS Between November 1997 an